BG108537A - Единична доза азитромицин - Google Patents

Единична доза азитромицин Download PDF

Info

Publication number: BG108537A
Authority: BG; Bulgaria
Prior art keywords: dose; azithromycin; use according; treatment; single dose
Prior art date: 2001-08-21

Application number

BG108537A

Other languages

Bulgarian (bg)

English (en)

Inventor

Michael Dunne

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-21

Filing date

2004-01-21

Publication date

2005-02-28

2004-01-21 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-02-28 Publication of BG108537A publication Critical patent/BG108537A/bg

Links

229960004099 azithromycin Drugs 0.000 title claims abstract description 44
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 44
206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 16
238000011282 treatment Methods 0.000 claims description 23
208000022760 infectious otitis media Diseases 0.000 claims description 17
230000037396 body weight Effects 0.000 claims description 9
108090000623 proteins and genes Proteins 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 description 16
241000606768 Haemophilus influenzae Species 0.000 description 8
206010033078 Otitis media Diseases 0.000 description 6
244000052769 pathogen Species 0.000 description 6
238000010172 mouse model Methods 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
241000588655 Moraxella catarrhalis Species 0.000 description 4
210000000959 ear middle Anatomy 0.000 description 4
238000000034 method Methods 0.000 description 4
241000193996 Streptococcus pyogenes Species 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000011556 gerbil model Methods 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
210000003454 tympanic membrane Anatomy 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
101150076489 B gene Proteins 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000754835 Sapovirus isolates Species 0.000 description 1
208000006374 Uterine Cervicitis Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
206010008323 cervicitis Diseases 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

BG108537A 2001-08-21 2004-01-21 Единична доза азитромицин BG108537A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31386701P	2001-08-21	2001-08-21

Publications (1)

Publication Number	Publication Date
BG108537A true BG108537A (bg)	2005-02-28

Family

ID=23217490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108537A BG108537A (bg)	2001-08-21	2004-01-21	Единична доза азитромицин

Country Status (25)

Country	Link
US (3)	US20030148964A1 (fr)
EP (1)	EP1418924A2 (fr)
JP (1)	JP2005501862A (fr)
KR (1)	KR20040032942A (fr)
AP (1)	AP1729A (fr)
BG (1)	BG108537A (fr)
BR (1)	BR0211830A (fr)
CA (1)	CA2458135A1 (fr)
CZ (1)	CZ2004232A3 (fr)
EA (1)	EA200400214A1 (fr)
EC (1)	ECSP044985A (fr)
GE (1)	GEP20063812B (fr)
HR (1)	HRP20040163A2 (fr)
HU (1)	HUP0401332A2 (fr)
IL (1)	IL159585A0 (fr)
IS (1)	IS7092A (fr)
MA (1)	MA27059A1 (fr)
MX (1)	MXPA04001605A (fr)
OA (1)	OA12845A (fr)
PL (1)	PL367888A1 (fr)
SK (1)	SK1012004A3 (fr)
TN (1)	TNSN04035A1 (fr)
WO (1)	WO2003018031A2 (fr)
YU (1)	YU8804A (fr)
ZA (1)	ZA200400804B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE421882T1 (de) *	2003-07-24	2009-02-15	Pliva Hrvatska D O O	Schnellösliches azithromycin in einzeldosisform
US6984403B2 (en)	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
CA2547597A1 (fr)	2003-12-04	2005-06-16	Pfizer Products Inc.	Compositions multiparticulaires a stabilite amelioree
ES2600577T3 (es)	2003-12-04	2017-02-09	Bend Research, Inc.	Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
KR100844628B1 (ko)	2003-12-04	2008-07-07	화이자 프로덕츠 인크.	제약상 다입자의 제조 방법
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
EP3067047B1 (fr)	2005-12-08	2022-04-20	Insmed Incorporated	Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires
US9119783B2 (en)	2007-05-07	2015-09-01	Insmed Incorporated	Method of treating pulmonary disorders with liposomal amikacin formulations
US20090005326A1 (en) *	2007-06-26	2009-01-01	Idexx Laboratories, Inc.	Single dose roxithromycin
US20090197956A1 (en) *	2008-02-04	2009-08-06	Arbor Pharmaceuticals, Inc.	Treatment of acute otitis media with xylitol and n-acetylcysteine
WO2009114810A2 (fr) *	2008-03-14	2009-09-17	The Florida International Uinversity Board Of Trustees	Utilisation d'ellagitannines comme inhibiteurs de la détection du quorum bactérien
CA2838188C (fr)	2011-06-04	2017-04-18	Rochester General Hospital Research Institute	Compositions et procedes associes a la proteine p6 de l'haemophilus influenzae
US10124066B2 (en)	2012-11-29	2018-11-13	Insmed Incorporated	Stabilized vancomycin formulations
LT3466432T (lt)	2014-05-15	2020-12-28	Insmed Incorporated	Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
EP3773505B1 (fr)	2018-03-30	2026-04-29	Insmed Incorporated	Procédés pour la fabrication continue de produits médicamenteux liposomaux
JP7449275B2 (ja)	2018-05-02	2024-03-13	インスメッドインコーポレイテッド	リポソーム薬物製剤の製造方法
WO2021163451A1 (fr) *	2020-02-14	2021-08-19	Asklepios Biopharmaceutical, Inc.	Procédé de traitement d'une toxicité associée à une thérapie génique avec des antibiotiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US53264A (en) *		1866-03-20		Improved ditching-machine
YU43116B (en) *	1979-04-02	1989-04-30	Pliva Pharm & Chem Works	Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
WO1989000576A1 (fr) *	1987-07-09	1989-01-26	Pfizer Inc.	Dihydrate d'azithromycine
WO1989002271A1 (fr) *	1987-09-10	1989-03-23	Pfizer	Azithromycine et derives utilises comme agents anti-protozoaires
YU45590A (sh) *	1990-03-07	1992-07-20	PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o.	Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
TW271400B (fr) *	1992-07-30	1996-03-01	Pfizer
US5686587A (en) *	1993-05-19	1997-11-11	Pfizer Inc.	Intermediate for azithromycin
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
HUT77530A (hu) *	1994-05-06	1998-05-28	Pfizer Inc.	Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
HRP980189B1 (en) *	1998-04-06	2004-04-30	Pliva Pharm & Chem Works	Novel 15-membered lactams ketolides
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US20040053264A1 (en) *	2002-02-01	2004-03-18	Park Sung Sup	Clinical panel assay using DNA chips

2002
- 2002-07-31 CA CA002458135A patent/CA2458135A1/fr not_active Abandoned
- 2002-07-31 EP EP02753170A patent/EP1418924A2/fr not_active Withdrawn
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Ceased
- 2002-07-31 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/fr not_active Ceased
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TNSN04035A1 (fr)	2006-06-01
BR0211830A (pt)	2004-09-08
US6987093B2 (en)	2006-01-17
CA2458135A1 (fr)	2003-03-06
SK1012004A3 (sk)	2005-04-01
ZA200400804B (en)	2005-05-03
MA27059A1 (fr)	2004-12-20
JP2005501862A (ja)	2005-01-20
US20050250712A1 (en)	2005-11-10
IL159585A0 (en)	2004-06-01
US20030148964A1 (en)	2003-08-07
MXPA04001605A (es)	2004-07-08
KR20040032942A (ko)	2004-04-17
CZ2004232A3 (cs)	2005-10-12
PL367888A1 (en)	2005-03-07
US20040023898A1 (en)	2004-02-05
IS7092A (is)	2003-12-23
AP1729A (en)	2007-03-26
US7067493B2 (en)	2006-06-27
HRP20040163A2 (en)	2005-02-28
AP2004002968A0 (en)	2004-03-31
YU8804A (sh)	2006-08-17
OA12845A (en)	2006-09-15
GEP20063812B (en)	2006-05-10
EA200400214A1 (ru)	2004-06-24
WO2003018031A3 (fr)	2003-10-02
ECSP044985A (es)	2004-04-28
EP1418924A2 (fr)	2004-05-19
WO2003018031A2 (fr)	2003-03-06
HUP0401332A2 (hu)	2004-11-29

Publication	Publication Date	Title
BG108537A (bg)	2005-02-28	Единична доза азитромицин
McCracken	1972	The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis
CN106620649A (zh)	2017-05-10	使用单剂量奥利万星的治疗方法
Amin	2018	Biological assessment of ozone therapy on experimental oral candidiasis in immunosuppressed rats
Marchi	1990	Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis
Vidal et al.	2021	Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite deoxycholic acid
Marshak et al.	1981	Recurrent pneumococcal otitis media in the chinchilla: a longitudinal study
McLinn	1995	Double blind and open label studies of azithromycin in the management of acute otitis media in children: a review
McCarty	1996	A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media
Lari et al.	2012	Comparison of cefuroxime and co-amoxiclav in the treatment of acute sinusitis in a sample of the Iranian population
Alper et al.	1996	Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible,-intermediate, and-resistant Streptococcus pneumoniae in the chinchilla
CN114375200A (zh)	2022-04-19	治疗传染病的药物和方法
Bentley et al.	1968	Lincomycin in the treatment of penicillin-resistant staphylococcal infections in children
AU2002313574A1 (en)	2003-03-10	Single dose azithromycin for treating respiratory infections
US20250120929A1 (en)	2025-04-17	Method of treating virus-associated infection using acetaminophen
AU2020203634B2 (en)	2024-05-16	Treating or preventing respiratory infection
Barlow et al.	2016	Infectious diseases and tropical medicine
RU2180532C2 (ru)	2002-03-20	Способ лечения папилломатоза
Flume	2008	A role for aerosolized antibiotics
Mattos Filho et al.	2006	Effect of betamethasone and diclofenac sodium on serum and tissue concentration of amoxicillin: in vivo study in rats
Shimizu et al.	1999	The haemodialysis patient who developed acute respiratory distress syndrome after a trip to a hot spring spa.
Dandekar et al.	2005	Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model
Golhar et al.	2020	CORONA VIRUS2019: INTRODUCTION AND ITS TREATMENTS
JPS59116217A (ja)	1984-07-05	マイコプラズマ感染症用薬
RU2306149C2 (ru)	2007-09-20	Способ лечения больных с затяжной пневмонией с применением препарата "рузам"